Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Annovis Bio, Inc. (ANVS) had Consolidated Net Income/Loss of $-17.61M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-17.61M |
|
-- |
|
-- |
|
$18.01M |
|
$-18.01M |
|
$0.41M |
|
$-17.61M |
|
$-17.61M |
|
$-17.61M |
|
$-17.61M |
|
|
Consolidated Net Income/Loss |
$-17.61M |
$-17.61M |
|
$-18.01M |
|
$-18.01M |
|
27.85M |
|
27.85M |
|
$-0.63 |
|
$-0.63 |
|
| Balance Sheet Financials | |
$16.24M |
|
-- |
|
-- |
|
$16.24M |
|
$12.79M |
|
-- |
|
$0.33M |
|
$13.12M |
|
$3.13M |
|
$3.13M |
|
$3.13M |
|
28.54M |
|
| Cash Flow Statement Financials | |
$-9.01M |
|
-- |
|
$3.70M |
|
$19.53M |
|
$14.22M |
|
$-5.31M |
|
$0.18M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.27 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.01M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-563.21% |
|
-563.21% |
|
-108.39% |
|
-563.21% |
|
$0.11 |
|
$-0.32 |
|
$-0.32 |
|